NZ597511A - Diazahomoadamantane derivatives and methods of use thereof - Google Patents
Diazahomoadamantane derivatives and methods of use thereofInfo
- Publication number
- NZ597511A NZ597511A NZ597511A NZ59751110A NZ597511A NZ 597511 A NZ597511 A NZ 597511A NZ 597511 A NZ597511 A NZ 597511A NZ 59751110 A NZ59751110 A NZ 59751110A NZ 597511 A NZ597511 A NZ 597511A
- Authority
- NZ
- New Zealand
- Prior art keywords
- diazatricyclo
- disorder
- undecane
- acetylcholine receptor
- nicotinic acetylcholine
- Prior art date
Links
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 abstract 2
- 230000006735 deficit Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108010052671 nicotinic receptor alpha4beta2 Proteins 0.000 abstract 2
- QZFQDVLIAQNSLM-UHFFFAOYSA-N 1,4-diazatricyclo[4.3.1.13,8]undecan-4-yl(thieno[2,3-c]pyridin-5-yl)methanone Chemical compound C=1C=2C=CSC=2C=NC=1C(=O)N1CC(C2)CN3CC1CC2C3 QZFQDVLIAQNSLM-UHFFFAOYSA-N 0.000 abstract 1
- HTIKEGIKZQYHTO-UHFFFAOYSA-N 2-(1,4-diazatricyclo[4.3.1.13,8]undecan-4-yl)-5-phenyl-1,3,4-oxadiazole Chemical compound C1C(C2)CC3CN2CC1CN3C(O1)=NN=C1C1=CC=CC=C1 HTIKEGIKZQYHTO-UHFFFAOYSA-N 0.000 abstract 1
- XGYFUALJXMFBSC-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-1,3-thiazol-2-yl]-1,4-diazatricyclo[4.3.1.13,8]undecane Chemical compound C1=CC(F)=CC=C1C1=CN=C(N2C3CC4CC(CN(C4)C3)C2)S1 XGYFUALJXMFBSC-UHFFFAOYSA-N 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- QMKNDDIPPJRAOJ-UHFFFAOYSA-N N-[3-(1,4-diazatricyclo[4.3.1.13,8]undecane-4-carbonyl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C(=O)N2C3CC4CC(CN(C4)C3)C2)=C1 QMKNDDIPPJRAOJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 abstract 1
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21847909P | 2009-06-19 | 2009-06-19 | |
| PCT/CN2010/000889 WO2010145208A1 (en) | 2009-06-19 | 2010-06-18 | Diazahomoadamantane derivatives and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ597511A true NZ597511A (en) | 2014-01-31 |
Family
ID=43354879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ597511A NZ597511A (en) | 2009-06-19 | 2010-06-18 | Diazahomoadamantane derivatives and methods of use thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8846661B2 (https=) |
| EP (1) | EP2443122B1 (https=) |
| JP (1) | JP2012530084A (https=) |
| KR (1) | KR20120044978A (https=) |
| CN (1) | CN102459268A (https=) |
| AU (1) | AU2010262643B2 (https=) |
| BR (1) | BRPI1015043A2 (https=) |
| CA (1) | CA2765466A1 (https=) |
| IL (2) | IL216883A (https=) |
| MX (1) | MX2011014019A (https=) |
| NZ (1) | NZ597511A (https=) |
| PE (1) | PE20121066A1 (https=) |
| RU (2) | RU2015110025A (https=) |
| SG (1) | SG176921A1 (https=) |
| WO (1) | WO2010145208A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2809028C (en) * | 2010-08-20 | 2019-04-09 | Research Triangle Institute | Nicotinic receptor compounds |
| CN103087001A (zh) * | 2011-11-03 | 2013-05-08 | 南京大学 | 香草酸的1，3，4-噁二唑衍生物及其制法和用途 |
| WO2014165090A1 (en) * | 2013-03-13 | 2014-10-09 | The Broad Institute, Inc. | Compounds for the treatment of tuberculosis |
| RU2552649C1 (ru) * | 2013-12-13 | 2015-06-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет тонких химических технологий имени М.В. Ломоносова" (МИТХТ им. М.В. Ломоносова) | Душистые 5-бензил-1,3-диазаадамантан-6-оны |
| WO2015103005A1 (en) * | 2014-01-03 | 2015-07-09 | Research Institute At Nationwide Children's Hospital | Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers |
| EP3623371A1 (en) | 2014-12-16 | 2020-03-18 | Axovant Sciences GmbH | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| CN107847494A (zh) | 2015-06-10 | 2018-03-27 | 阿考温特科学股份有限公司 | 作为α7‑烟碱乙酰胆碱受体激动剂的氨基苯并异噁唑化合物 |
| JP2018523707A (ja) | 2015-08-12 | 2018-08-23 | アクソバント サイエンシズ ゲーエムベーハー | α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物 |
| IL294124B2 (en) | 2015-12-10 | 2024-02-01 | Ptc Therapeutics Inc | Methods for treating huntington's disease |
| US11407753B2 (en) | 2017-06-05 | 2022-08-09 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| US11382918B2 (en) | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
| WO2019005993A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| EP3749666A1 (en) * | 2018-02-08 | 2020-12-16 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
| MX2020009957A (es) | 2018-03-27 | 2021-01-15 | Ptc Therapeutics Inc | Compuestos para el tratamiento de enfermedad de hungtinton. |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| PL3814357T3 (pl) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics, Inc. | Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona |
| EP3814345B8 (en) | 2018-06-27 | 2024-10-30 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| WO2020231977A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4557865A (en) * | 1984-05-07 | 1985-12-10 | Pennwalt Corporation | Substituted 4-azatricyclo[4.3.1.13,8 ]undecane compounds |
| NZ321970A (en) * | 1995-11-02 | 2000-02-28 | Neurosearch As | Fused tropane-derivatives as neurotransmitter reuptake inhibitors |
| US6093724A (en) * | 1998-08-18 | 2000-07-25 | Ucb, S.A. | Muscarinic agonists and antagonists |
| US6468998B1 (en) * | 1998-11-02 | 2002-10-22 | Mitsubishi Pharma Corporation | Pyrrolidine compounds and medicinal utilization thereof |
| EP1395257A1 (en) * | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| US20050065178A1 (en) * | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| DE602004006767T2 (de) * | 2003-09-26 | 2008-02-07 | Astrazeneca Ab | Nichtamidnonane |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| TW200840569A (en) * | 2007-03-13 | 2008-10-16 | Targacept Inc | Sub-type selective amides of diazabicycloalkanes |
| EP2129672B1 (en) * | 2007-03-23 | 2011-05-18 | Abbott Laboratories | Azaadamantane ester and carbamate derivatives and methods of use thereof |
| CA2679885A1 (en) * | 2007-03-23 | 2008-10-02 | Abbott Laboratories | Aminomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs) |
| ATE538122T1 (de) * | 2007-03-23 | 2012-01-15 | Abbott Lab | Acetamid- und carboxamid-derivate von azaadamantan sowie verfahren zu ihrer verwendung |
| JP5540099B2 (ja) * | 2009-09-14 | 2014-07-02 | スベン ライフ サイエンシズ リミティド | ５−ｈｔ４受容体リガンドとしての１，２−ジヒドロ−２−オキソキノリン化合物 |
-
2010
- 2010-06-18 AU AU2010262643A patent/AU2010262643B2/en not_active Ceased
- 2010-06-18 MX MX2011014019A patent/MX2011014019A/es active IP Right Grant
- 2010-06-18 BR BRPI1015043A patent/BRPI1015043A2/pt not_active IP Right Cessation
- 2010-06-18 JP JP2012515322A patent/JP2012530084A/ja not_active Ceased
- 2010-06-18 NZ NZ597511A patent/NZ597511A/en not_active IP Right Cessation
- 2010-06-18 CA CA2765466A patent/CA2765466A1/en not_active Abandoned
- 2010-06-18 CN CN2010800368013A patent/CN102459268A/zh active Pending
- 2010-06-18 PE PE2011002111A patent/PE20121066A1/es not_active Application Discontinuation
- 2010-06-18 US US12/818,764 patent/US8846661B2/en not_active Expired - Fee Related
- 2010-06-18 EP EP10788604.6A patent/EP2443122B1/en not_active Not-in-force
- 2010-06-18 WO PCT/CN2010/000889 patent/WO2010145208A1/en not_active Ceased
- 2010-06-18 KR KR1020127001339A patent/KR20120044978A/ko not_active Withdrawn
- 2010-06-18 RU RU2015110025/04A patent/RU2015110025A/ru not_active Application Discontinuation
- 2010-06-18 SG SG2011094141A patent/SG176921A1/en unknown
- 2010-06-18 RU RU2012101784/04A patent/RU2549551C2/ru not_active IP Right Cessation
-
2011
- 2011-12-08 IL IL216883A patent/IL216883A/en not_active IP Right Cessation
-
2015
- 2015-01-21 IL IL236830A patent/IL236830A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102459268A (zh) | 2012-05-16 |
| MX2011014019A (es) | 2012-02-22 |
| KR20120044978A (ko) | 2012-05-08 |
| IL236830A0 (en) | 2015-03-31 |
| PE20121066A1 (es) | 2012-09-13 |
| EP2443122A4 (en) | 2012-12-19 |
| RU2012101784A (ru) | 2013-07-27 |
| JP2012530084A (ja) | 2012-11-29 |
| US20100324027A1 (en) | 2010-12-23 |
| RU2015110025A (ru) | 2015-08-20 |
| AU2010262643A1 (en) | 2012-02-02 |
| CA2765466A1 (en) | 2010-12-23 |
| BRPI1015043A2 (pt) | 2019-07-09 |
| AU2010262643B2 (en) | 2015-02-19 |
| SG176921A1 (en) | 2012-01-30 |
| EP2443122A1 (en) | 2012-04-25 |
| US8846661B2 (en) | 2014-09-30 |
| IL216883A (en) | 2015-02-26 |
| IL216883A0 (en) | 2012-02-29 |
| RU2549551C2 (ru) | 2015-04-27 |
| EP2443122B1 (en) | 2014-03-05 |
| WO2010145208A1 (en) | 2010-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ597511A (en) | Diazahomoadamantane derivatives and methods of use thereof | |
| NO20091478L (no) | Aminometyl-4-imidazoler | |
| DE602007010303D1 (de) | Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen | |
| NZ592792A (en) | Heterocyclically substituted aryl compounds as hif inhibitors | |
| NZ600674A (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| JP2007510689A5 (https=) | ||
| NO20082059L (no) | Ny polymorf form og den amorfe formen av 5-klor-N({(5S)-2-okso-3[4-(3-okso-4-morfolinyl)-fenyl]-1,3-oksazolidin-5-yl}-metyl)-2-tiofenkarboksamid | |
| JP2008539195A5 (https=) | ||
| CN109153649A (zh) | 烟碱乙酰胆碱受体的变构调节剂 | |
| JP2008539195A (ja) | 新規のオキサジアゾール誘導体及びそれらの医学的使用 | |
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| RU2012102908A (ru) | Азаадамантановые производные и способы применения | |
| JP2009520685A5 (https=) | ||
| RU2010130175A (ru) | Производные бензотиазола и бензоксазола и способы их применения | |
| WO2008155572A3 (en) | Fused quinoline derivatives useful as gaba modulators | |
| IL295076B2 (en) | Piperidinone derivatives as MDM2 inhibitors for cancer treatment | |
| NZ603427A (en) | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) | |
| NZ596753A (en) | Phenoxymethyl heterocyclic compounds | |
| ZA201302480B (en) | Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders | |
| WO2013186792A3 (en) | Process for preparation of azilsartan medoxomil and its salts | |
| NZ594404A (en) | Novel polymorphic forms of 3-(1-{ 3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl} -6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof | |
| JP2012520238A5 (https=) | ||
| NO20075022L (no) | (7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav | |
| RU2010129078A (ru) | Производные циклопропиламина | |
| JP2009528284A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: ABBVIE INC., US Effective date: 20130801 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 JUN 2017 BY THOMSON REUTERS Effective date: 20140619 |
|
| LAPS | Patent lapsed |